Virpax Pharmaceuticals (VRPX) late Tuesday reported positive results from a dose range finding study of its Probudur pain relief treatment in beagle dogs, further paving the way for its investigational new drug application.

The study assessed the tolerance of Probudur when administered by subcutaneous injection in a dose-escalating manner. The company said all the dogs in the study showed positive tolerance to Probudur, with no adverse effects.

Study results indicate that doses of LBL100 up to 90 mg/kg are "well tolerated" by beagle dogs, Virpax said.

Its shares were up 36% in recent premarket activity Wednesday.